EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy

Donna Liao, Mahmood Aminilari, Xiang Y Ye, Ur Metser, Amit Singnurkar, Sita Bhella, Michael Crump, Robert Kridel, Vishal Kukreti, John Kuruvilla, Anca Prica, Abi Vijenthira und 4 weitere

Practical Radiation Oncology · 2026

DOI: 10.1016/j.prro.2026.01.017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Practical Radiation Oncology, 2026. Verfasst von Donna Liao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Faculty of Medicine, Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Hodgkin Disease, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Princess Margaret Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate real-world management strategies and outcomes for patients with Hodgkin lymphoma (HL) with a partial metabolic response (PMR) on an end-of-chemotherapy (EOC) fluorodeoxyglucose-positron emission tomography (PET) scan and assess whether dynamic changes in maximum standardized uptake value (SUVmax) could refine risk stratification. METHODS AND MATERIALS: Multicenter, retrospective cohort study of patients with HL treated from January 1, 2009, to September 30, 2021. PMR was defined as a Deauville score of 4 on the EOC-PET scan, with an SUVmax value lower than the staging PET scan. First-line chemotherapy was predominantly adriamycin, bleomycin, vinblastine, and dacarbazine (62.7%), or adriamycin, bleomycin, vinblastine, and dacarbazine-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (28.4%). The primary endpoint was progression-free survival (PFS). Cox proportional hazards models adjusted for stage and EOC-avid sites quantified outcomes; SUVmax value kinetics (interim-to-EOC) were explored within the radiation therapy (RT) cohort. RESULTS: Among 836 patients with EOC-PET scans, 67 met PMR criteria; median follow-up was 3.2 years (range, 0.1-12.6). Post-EOC-PET scan management included involved-site RT (n = 38), salvage chemotherapy ± autologous stem-cell transplantation (n = 14), or observation with serial PET scans (n = 12). RT recipients had more early-stage disease (55.3% vs 21.4%), fewer EOC-avid sites (median, 1 vs 2), and lower EOC SUVmax values (median, 4.7 vs 10.2) than those receiving systemic therapy. Two-year PFS was 84.2% after RT, 52.7% after salvage chemotherapy, and 74.1% with observation (log-rank P = .057). On multivariable analysis, salvage chemotherapy (hazard ratio [HR], 5.82; 95% CI, 1.14-29.81; P = .03) and observation (HR, 5.74; 95% CI, 1.12-29.39; P = .03) were associated with higher progression risk versus RT. Within the RT cohort, rising SUVmax values between interim and EOC-PET scans (HR, 7.21; 95% CI, 1.17-44.35; P = .033) and higher absolute EOC SUVmax values (HR per unit, 1.35; 95% CI, 1.02-1.79; P = .036) predicted inferior PFS. CONCLUSIONS: Most patients with HL with PMR achieve durable remission with consolidative RT alone, avoiding salvage chemotherapy and transplantation. Dynamic changes in SUVmax values-especially a rising SUVmax value between interim and EOC-PET scans-identify a high-risk subset potentially warranting treatment intensification. Prospective studies integrating novel agents and PET scan metrics are needed to personalize therapy for this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsHumansRetrospective StudiesFemaleMaleAdultPositron-Emission TomographyMiddle AgedFluorodeoxyglucose F18Treatment OutcomeAdolescentYoung Adult

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Temerty Faculty of Medicine, Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
  • Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto Ontario, Canada.
  • Joint Department of Medical Imaging, University Medical Imaging Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Department of Precision Diagnostics and Therapeutics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

Förderung

  • Princess Margaret Cancer Foundation

Zitieren

APA

Liao, D., Aminilari, M., Ye, X. Y., Metser, U., Singnurkar, A., Bhella, S., Crump, M., Kridel, R., Kukreti, V., Kuruvilla, J., Prica, A., Vijenthira, A., Cheung, M., Rodin, D., Tsao, M., & Hodgson, D. (2026). Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2026.01.017

Vancouver

Liao D, Aminilari M, Ye XY, Metser U, Singnurkar A, Bhella S, et al. Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy. Practical Radiation Oncology. 2026. doi:10.1016/j.prro.2026.01.017

BibTeX
@article{Liao2026,
  author = {Liao, Donna and Aminilari, Mahmood and Ye, Xiang Y and Metser, Ur and Singnurkar, Amit and Bhella, Sita and Crump, Michael and Kridel, Robert and Kukreti, Vishal and Kuruvilla, John and Prica, Anca and Vijenthira, Abi and Cheung, Matthew and Rodin, Danielle and Tsao, May and Hodgson, David},
  title = {Management and Outcomes for Patients With Hodgkin Lymphoma With Partial Metabolic Response After First-Line Systemic Therapy},
  journal = {Practical Radiation Oncology},
  year = {2026},
  doi = {10.1016/j.prro.2026.01.017}
}
Kostenlos starten →